The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
Rheum Dis Clin North Am
; 50(2): 181-199, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38670720
ABSTRACT
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this immune activation can lead to immune-related adverse events (irAEs), including rheumatic manifestations (Rh-irAEs). Rh-irAEs mimic primary rheumatic diseases including arthritis, polymyalgia rheumatica, myositis, vasculitis, sarcoidosis, and sicca. This article summarizes the latest evidence regarding the utility of laboratory investigations in Rh-irAEs.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Reumáticas
/
Inhibidores de Puntos de Control Inmunológico
Límite:
Humans
Idioma:
En
Revista:
Rheum Dis Clin North Am
Asunto de la revista:
REUMATOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Canadá
Pais de publicación:
Estados Unidos